腹膜播種陽性または腹腔細胞診陽性の胃癌に対する集学的治療の開発

1. 日本胃癌学会編. 日本胃癌学会編．胃癌治療ガイドライン第 5 版医師用 2018 年 1

月改訂．東京，金原出版 2018.

2. Ajani JA, D'Amico TA, Almhanna K, Bentrem DJ, Chao J, Das P, et al. Gastric Cancer,

Version 3.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc

Netw. 2016;14(10):1286-312.

3. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, et al. Gastric

cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann

Oncol. 2016;27(suppl 5):v38-v49.

4. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin

versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a

phase III trial. Lancet Oncol. 2008;9(3):215-21.

5. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin

versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric

cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666-73.

6. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study

comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients

with advanced gastric cancer. Ann Oncol. 2015;26(1):141-8.

54

7. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab

plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced

gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind,

randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224-35.

8. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment

of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a

phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687-97.

9. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with

advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at

least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a

randomised, double-blind, placebo-controlled, phase 3 trial. Lancet.

2017;390(10111):2461-71.

10. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy

plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single

non-curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol.

2016;17(3):309-18.

11. Terashima M, Yoshida K, Rha SY, Bae JM, Li G, Katai H, et al. International

retrospective cohort study of conversion therapy for stage IV gastric cancer 1 (CONVO-

55

GC-1). J Clin Oncol. 2018;36:4042-.

12. Sugarbaker PH, Yonemura Y. Clinical pathway for the management of resectable gastric

cancer with peritoneal seeding: Best palliation with a ray of hope for cure. Oncology.

2000;58(2):96-107.

13. Fujimoto S, Takahashi M, Kobayashi K, Kure M, Mutou T, Masaoka H, et al. Relation

between clinical and histologic outcome of intraperitoneal hyperthermic perfusion for

patients with gastric cancer and peritoneal metastasis. Oncology. 1993;50(5):338-43.

14. Shirao K, Boku N, Yamada Y, Yamaguchi K, Doi T, Goto M, et al. Randomized Phase III

study of 5-fluorouracil continuous infusion vs. sequential methotrexate and 5-fluorouracil

therapy in far advanced gastric cancer with peritoneal metastasis (JCOG0106). Jpn J Clin

Oncol. 2013;43(10):972-80.

15. Yang S, Feng R, Pan ZC, Jiang T, Xu Q, Chen Q. A Comparison of Intravenous plus

Intraperitoneal Chemotherapy with Intravenous Chemotherapy Alone for the Treatment of

Gastric Cancer: A Meta-Analysis. Sci Rep. 2015;5:12538.

16. Miyashiro I, Furukawa H, Sasako M, Yamamoto S, Nashimoto A, Nakajima T, et al.

Randomized clinical trial of adjuvant chemotherapy with intraperitoneal and intravenous

cisplatin followed by oral fluorouracil (UFT) in serosa-positive gastric cancer versus

curative resection alone: final results of the Japan Clinical Oncology Group trial

JCOG9206-2. Gastric Cancer. 2011;14(3):212-8.

56

17. Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, et al. Enhanced efficacy of

postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3

randomized trial (AMC0101). Cancer Chemother Pharmacol. 2014;73(1):139-49.

18. Markman M, Rowinsky E, Hakes T, Reichman B, Jones W, Lewis JL, Jr., et al. Phase I

trial of intraperitoneal taxol: a Gynecoloic Oncology Group study. J Clin Oncol.

1992;10(9):1485-91.

19. Francis P, Rowinsky E, Schneider J, Hakes T, Hoskins W, Markman M. Phase I feasibility

and pharmacologic study of weekly intraperitoneal paclitaxel: a Gynecologic Oncology

Group pilot Study. J Clin Oncol. 1995;13(12):2961-7.

20. Markman M, Brady MF, Spirtos NM, Hanjani P, Rubin SC. Phase II trial of

intraperitoneal paclitaxel in carcinoma of the ovary, tube, and peritoneum: a Gynecologic

Oncology Group Study. J Clin Oncol. 1998;16(8):2620-4.

21. Armstrong DK, Bundy B, Wenzel L, Huang HQ, Baergen R, Lele S, et al. Intraperitoneal

cisplatin and paclitaxel in ovarian cancer. N Engl J Med. 2006;354(1):34-43.

22. Fushida S, Furui N, Kinami S, Ninomiya I, Fujimura T, Nishimura G, et al.

[Pharmacologic study of intraperitoneal paclitaxel in gastric cancer patients with

peritoneal dissemination]. Gan To Kagaku Ryoho. 2002;29(12):2164-7.

23. Kodera Y, Ito Y, Ito S, Ohashi N, Mochizuki Y, Yamamura Y, et al. Intraperitoneal

paclitaxel: a possible impact of regional delivery for prevention of peritoneal

57

carcinomatosis in patients with gastric carcinoma. Hepatogastroenterology.

2007;54(75):960-3.

24. Imano M, Peng YF, Itoh T, Nishikawa M, Satou T, Yasuda A, et al. A preliminary study of

single intraperitoneal administration of paclitaxel followed by sequential systemic

chemotherapy with S-1 plus paclitaxel for advanced gastric cancer with peritoneal

metastasis. Anticancer Res. 2012;32(9):4071-5.

25. Ishigami H, Kitayama J, Otani K, Kamei T, Soma D, Miyato H, et al. Phase I

pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined

with S-1 for advanced gastric cancer. Oncology. 2009;76(5):311-4.

26. Narahara H, Fujitani K, Takiuchi H, Sugimoto N, Inoue K, Uedo N, et al. Phase II study

of a combination of S-1 and paclitaxel in patients with unresectable or metastatic gastric

cancer. Oncology. 2008;74(1-2):37-41.

27. Koizumi W, Kurihara M, Nakano S, Hasegawa K, Study SCGC. Phase II study of S-1, a

novel oral derivative of 5-fluorouracil, in advanced gastric cancer. Oncology.

2000;58(3):191-7.

28. Kobayashi M, Sakamoto J, Namikawa T, Okamoto K, Okabayashi T, Ichikawa K, et al.

Pharmacokinetic study of paclitaxel in malignant ascites from advanced gastric cancer

patients. World J Gastroenterol. 2006;12(9):1412-5.

29. Ishigami H, Kitayama J, Kaisaki S, Hidemura A, Kato M, Otani K, et al. Phase II study of

58

weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric

cancer with peritoneal metastasis. Ann Oncol. 2010;21(1):67-70.

30. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2

trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of

gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354-8.

31. Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase

III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin

Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX-GC

Trial. J Clin Oncol. 2018;36(19):1922-9.

32. Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Surgery after

intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or

positive peritoneal cytology findings. Gastric Cancer. 2017;20(Suppl 1):128-34.

33. Kitayama J, Ishigami H, Yamaguchi H, Yamashita H, Emoto S, Kaisaki S, et al. Salvage

gastrectomy after intravenous and intraperitoneal paclitaxel (PTX) administration with

oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites.

Ann Surg Oncol. 2014;21(2):539-46.

34. 胃癌研究会編. 胃癌取扱い規約第 12 版．東京，金原出版. 1993.

35. 日本胃癌学会編. 胃癌取扱い規約改訂第 14 版．東京，金原出版. 2010.

59

36. 日本胃癌学会編. 胃癌治療ガイドライン第 4 版医師用 2014 年 5 月改訂．東京，

金原出版. 2014.

37. Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M, et al.

Neoadjuvant chemotherapy with S-1 and cisplatin followed by D2 gastrectomy with paraaortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br

J Surg. 2014;101(6):653-60.

38. Kinoshita J, Fushida S, Tsukada T, Oyama K, Okamoto K, Makino I, et al. Efficacy of

conversion gastrectomy following docetaxel, cisplatin, and S-1 therapy in potentially

resectable stage IV gastric cancer. Eur J Surg Oncol. 2015;41(10):1354-60.

39. Ishigami H, Yamaguchi H, Yamashita H, Asakage M, Kitayama J. Gastrectomy after

response to intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal

metastasis or positive peritoneal cytology. Ann Oncol. 2017;28 (suppl_5):v209-v68.

40. Aizawa M, Ishigami H, Omori T, Kodera Y, Fukushima R, Imano M, et al. Gastrectomy

after intraperitoneal plus systemic chemotherapy for gastric cancer patients with

peritoneal metastasis or positive peritoneal cytology: analysis of 124 patients from four

clinical trials. 11th International Workshop on Peritoneal Surface Malignancy 2018 Sept

9-10: Abstr C26.

60

謝辞

本研究を実施するにあたり、本学大学院医学系研究科腫瘍外科学の石原総一郎教授、

名川弘一元教授、北山丈二前准教授をはじめとする先生方および院内関連部署のスタ

ッフの皆様には多くのご支援とご指導を賜りました。ここに厚く感謝を申し上げます。

61

...